34. Sledge GW Jr et al. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial. Proc ASCO 1997; Abstract 2.

35. Kurosumi M et al.Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000;7:945-8. Abstract

36. Mori K et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000;17:33-8. Abstract

37. Schuller J et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291-7. Abstract

38. Takahashi H et al. Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment. Int J Oncol 2000;17:1205-11. Abstract

39. Toi M et al. Role of thymidine phosphorylase for predicting the prognosis and therapeutic effects of 5 ’-deoxy-5-fluorouridine, an intermediate form of capecitabine,in early breast cancer patients: Findings from a randomized controlled trial. Proc ASCO 2001; Abstract 120.

40. Tonkin K et al. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere ®) combined with intermittent capecitabine (Xeloda ®) for patients with anthracycline pre-treated metastatic breast cancer. Proc ASCO 2001; Abstract 2016.

41. Venturini M et al. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated,advanced breast cancer patients. Proc ASCO 2000; Abstract 419.

42. Verweij J. Rational design of new tumor-activated cytotoxic agents. Oncology 1999;57 Suppl 1:9-15. Abstract

43. Endo M et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5 ’-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999;83:127-34. Abstract

44. Fujimoto-Ouchi K et al. Schedule dependency of antitumor activity in combination therapy with capecitabine/5 ’-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7:1079-86. Abstract

45. Kono T et al. Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem 2001;49:131-8. Abstract

OTHER CLINICAL TRIALS

NCI-00-C-0149: Phase II Pilot Study of cDNA Microarray as a Measure of Tumor Response to Neoadjuvant Docetaxel and Capecitabine Followed by Surgery and Adjuvant Doxorubicin and Cyclophosphamide in Patients with Stage II or III Breast Cancer. Protocol